MC

McKesson Corporation

MCKHealthcareNASDAQ

Medical Distribution

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$403.43B
+12.4% YoY
Net Income
$4.76B
+44.5% YoY
EBITDA
$7.18B
+36.4% YoY
Free Cash Flow
$6.80B

Scan Results

Daily timeframe
DateIndicatorDetails
Aug 31 MACD Positive CrossoverHistogram +0.8358, positive momentum
Aug 29 MACD Positive CrossoverHistogram +0.8358, positive momentum
About McKesson Corporation

Headquartered within the healthcare sector, McKesson Corporation focuses on Medical Distribution services and products. McKesson Corporation provides healthcare services in the United States and internationally. At a $103.66B market cap, McKesson Corporation ranks as a large-cap company within healthcare. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions.

Where MCK stands vs its 150-day and 200-day moving averages

As of the August 31, 2026 close, MCK finished 5.80% above its 150-day moving average ($844.45) and 6.26% above its 200-day moving average ($840.74). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is MCK overbought or oversold?

At the August 31, 2026 close, MCK's RSI(14) was 53.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$103.66B
P/E (TTM)23.82
Fwd P/E17.62
EPS$37.32
Beta0.31
52W Change+28.6%
Dividend Yield0.41%
Analysis

On the balance sheet, MCK has $5.16B in cash with $11.80B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $6.80B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROA of 4.7% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $276.71B (2023) to $403.43B (2026), reflecting a 46% increase over the period.

The relatively low beta of 0.31 suggests MCK is a less volatile holding compared to the broader index. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence McKesson Corporation's trajectory.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms